Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.27)
# 4,404
Out of 5,154 analysts
8
Total ratings
28.57%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: In-Line | $73 → $110 | $95.94 | +14.65% | 2 | Mar 5, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $38.23 | +25.56% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $10.28 | +191.83% | 2 | Mar 22, 2023 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $28.34 | +41.14% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $0.63 | +3,539.82% | 1 | May 25, 2021 |
Incyte
Mar 5, 2026
Maintains: In-Line
Price Target: $73 → $110
Current: $95.94
Upside: +14.65%
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $38.23
Upside: +25.56%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $10.28
Upside: +191.83%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $28.34
Upside: +41.14%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $0.63
Upside: +3,539.82%